Skip to main content
Erschienen in: Surgery Today 10/2022

24.02.2022 | Original Article

The C-reactive protein to albumin ratio is a prognostic factor for stage I non-small cell lung cancer in elderly patients: JACS1303

verfasst von: Takuro Miyazaki, Hisashi Saji, Hiroshige Nakamura, Takeshi Nagayasu, Norihito Okumura, Masanori Tsuchida, Makoto Sonobe, Keiju Aokage, Masayuki Nakao, Tomohiro Haruki, Morihito Okada, Kenji Suzuki, Masayuki Chida, Ichiro Yoshino, Committee for Scientific Affairs, The Japanese Association for Chest Surgery

Erschienen in: Surgery Today | Ausgabe 10/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To establish the prognostic significance of C-reactive protein (CRP) and albumin in octogenarians with non-small cell lung cancer (NSCLC) based on the study of the Japanese Association for Chest Surgery (JACS 1303).

Methods

A total of 618 octogenarians with pathological stage I NSCLC, who underwent pulmonary resection, were included in the analysis. We conducted multivariable Cox regression analysis to evaluate the CRP to albumin ratio (CAR) as a potential prognostic factor. Other clinicopathological factors were also evaluated.

Results

The median age was 82 years. Operations included lobectomy (n = 388; 62.8%) segmentectomy (n = 95; 15%), and wedge resection (n = 135; 22%). Pathological stage IA was diagnosed in 380 (61.5%) patients. The 3-year (OS) and cancer-specific survival (CS) rates were 86.7% and 94.6%, respectively. OS was significantly higher for patients with low CAR (< 0.106) than for those with high CAR (≥ 0.106) (hazard ratio = 3.13, 95% confidence interval: 1.99–4.93, p < 0.0001). Univariate analysis identified sex, poor performance status, smoking status, comorbidity, solid tumor, histology, high Glasgow prognostic scale, and high CAR as significant prognostic factors. Multivariate analysis identified only the CAR as a significant prognostic factor for both OS and CS.

Conclusions

Our analysis of the nationwide data demonstrated that the CAR is a useful prognostic factor for elderly patients with stage I NSCLC.
Literatur
2.
Zurück zum Zitat Shimizu H, Okada M, Toh Y, Doki Y, Endo S, Fukuda H, et al. Thoracic and cardiovascular surgeries in Japan during 2018: Annual Report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2021;69:179–212.PubMedCrossRef Shimizu H, Okada M, Toh Y, Doki Y, Endo S, Fukuda H, et al. Thoracic and cardiovascular surgeries in Japan during 2018: Annual Report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2021;69:179–212.PubMedCrossRef
3.
Zurück zum Zitat Saji H, Ueno T, Nakamura H. Prospective observational cohort study of postoperative risk and prognosis scoring for elderly patients with medically operable lung cancer (JACS1303). Gen Thorac Cardiovasc Surg. 2016;64:634–5.PubMedCrossRef Saji H, Ueno T, Nakamura H. Prospective observational cohort study of postoperative risk and prognosis scoring for elderly patients with medically operable lung cancer (JACS1303). Gen Thorac Cardiovasc Surg. 2016;64:634–5.PubMedCrossRef
4.
Zurück zum Zitat Saji H, Ueno T, Nakamura H, Okumura N, Tsuchida M, Sonobe M, et al. A proposal for a comprehensive risk scoring system for predicting postoperative complications in octogenarian patients with medically operable lung cancer: JACS1303. Eur J Cardiothorac Surg. 2018;53:835–41.PubMedCrossRef Saji H, Ueno T, Nakamura H, Okumura N, Tsuchida M, Sonobe M, et al. A proposal for a comprehensive risk scoring system for predicting postoperative complications in octogenarian patients with medically operable lung cancer: JACS1303. Eur J Cardiothorac Surg. 2018;53:835–41.PubMedCrossRef
5.
Zurück zum Zitat Hino H, Karasaki T, Yoshida Y, Fukami T, Sano A, Tanaka M, et al. Risk factors for postoperative complications and long-term survival in lung cancer patients older than 80 years. Eur J Cardiothorac Surg. 2018;53:980–6.PubMedCrossRef Hino H, Karasaki T, Yoshida Y, Fukami T, Sano A, Tanaka M, et al. Risk factors for postoperative complications and long-term survival in lung cancer patients older than 80 years. Eur J Cardiothorac Surg. 2018;53:980–6.PubMedCrossRef
6.
Zurück zum Zitat Okami J, Higashiyama M, Asamura H, Goya H, Koshiishi Y, Sohara Y, et al. Pulmonary resection in patients aged 80 years or over with clinical stage I non-small cell lung cancer: Prognostic factors for overall survival and risk factors for postoperative complications. J Thorac Oncol. 2009;4:1247–53.PubMedCrossRef Okami J, Higashiyama M, Asamura H, Goya H, Koshiishi Y, Sohara Y, et al. Pulmonary resection in patients aged 80 years or over with clinical stage I non-small cell lung cancer: Prognostic factors for overall survival and risk factors for postoperative complications. J Thorac Oncol. 2009;4:1247–53.PubMedCrossRef
7.
Zurück zum Zitat Miyazaki T, Yamasaki N, Tsuchiya T, Matsumoto K, Kunizaki M, Taniguchi D, et al. Inflammation-based scoring is a useful prognostic predictor of pulmonary resection for elderly patients with clinical stage I non-small-cell lung cancer. Eur J Cardiothorac Surg. 2015;47:e140–5.PubMedCrossRef Miyazaki T, Yamasaki N, Tsuchiya T, Matsumoto K, Kunizaki M, Taniguchi D, et al. Inflammation-based scoring is a useful prognostic predictor of pulmonary resection for elderly patients with clinical stage I non-small-cell lung cancer. Eur J Cardiothorac Surg. 2015;47:e140–5.PubMedCrossRef
8.
Zurück zum Zitat Kobayashi S, Karube Y, Matsumura Y, Nishiura M, Inoue T, Araki O, et al. Inflammatory risk factors for early recurrence of non-small cell lung cancer within one year following curative resection. World J Surg. 2020;44:3510–21.PubMedCrossRef Kobayashi S, Karube Y, Matsumura Y, Nishiura M, Inoue T, Araki O, et al. Inflammatory risk factors for early recurrence of non-small cell lung cancer within one year following curative resection. World J Surg. 2020;44:3510–21.PubMedCrossRef
9.
Zurück zum Zitat Wang J, Hui Z, Men Y, Kan J, Sun X, Deng L, et al. Systemic inflammation-immune status predicts survival in stage III-n2 non-small cell lung cancer. Ann Thorac Surg. 2019;108:1701–9.PubMedCrossRef Wang J, Hui Z, Men Y, Kan J, Sun X, Deng L, et al. Systemic inflammation-immune status predicts survival in stage III-n2 non-small cell lung cancer. Ann Thorac Surg. 2019;108:1701–9.PubMedCrossRef
10.
Zurück zum Zitat Proctor MJ, Morrison DS, Talwar D, Balmer SM, O’Reilly DSJ, Foulis AK, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: A Glasgow Inflammation Outcome Study. Br J Cancer. 2011;104:726–34.PubMedPubMedCentralCrossRef Proctor MJ, Morrison DS, Talwar D, Balmer SM, O’Reilly DSJ, Foulis AK, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: A Glasgow Inflammation Outcome Study. Br J Cancer. 2011;104:726–34.PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, et al. The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol. 2015;22:803–10.PubMedCrossRef Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, et al. The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol. 2015;22:803–10.PubMedCrossRef
12.
Zurück zum Zitat Baldessari C, Guaitoli G, Valoriani F, Bonacini R, Marcheselli R, Reverberi L, et al. Impact of body composition, nutritional and inflammatory status on outcome of non-small cell lung cancer patients treated with immunotherapy. Clinical Nutrit ESPEN. 2021;43:64–75.CrossRef Baldessari C, Guaitoli G, Valoriani F, Bonacini R, Marcheselli R, Reverberi L, et al. Impact of body composition, nutritional and inflammatory status on outcome of non-small cell lung cancer patients treated with immunotherapy. Clinical Nutrit ESPEN. 2021;43:64–75.CrossRef
13.
Zurück zum Zitat Ni XF, Wu J, Ji M, Shao YJ, Xu B, Jiang JT, et al. Effect of C-reactive protein/albumin ratio on prognosis in advanced non–small-cell lung cancer. Asia Pac J Clin Oncol. 2018;14:402–9.PubMedCrossRef Ni XF, Wu J, Ji M, Shao YJ, Xu B, Jiang JT, et al. Effect of C-reactive protein/albumin ratio on prognosis in advanced non–small-cell lung cancer. Asia Pac J Clin Oncol. 2018;14:402–9.PubMedCrossRef
14.
Zurück zum Zitat Zhang F, Ying L, Jin J, Chen K, Zhang N, Wu J, et al. The C-reactive protein/albumin ratio predicts long-term outcomes of patients with operable non-small cell lung cancer. Oncotarget. 2017;8:8835–42.PubMedCrossRef Zhang F, Ying L, Jin J, Chen K, Zhang N, Wu J, et al. The C-reactive protein/albumin ratio predicts long-term outcomes of patients with operable non-small cell lung cancer. Oncotarget. 2017;8:8835–42.PubMedCrossRef
15.
Zurück zum Zitat Miyazaki T, Yamasaki N, Tsuchiya T, Matsumoto K, Kunizaki M, Kamohara R, et al. Ratio of C-reactive protein to albumin is a prognostic factor for operable non-small-cell lung cancer in elderly patients. Surg Today. 2017;47:836–43.PubMedCrossRef Miyazaki T, Yamasaki N, Tsuchiya T, Matsumoto K, Kunizaki M, Kamohara R, et al. Ratio of C-reactive protein to albumin is a prognostic factor for operable non-small-cell lung cancer in elderly patients. Surg Today. 2017;47:836–43.PubMedCrossRef
16.
Zurück zum Zitat Worrall SF. TNM Classification of malignant tumours. Br J Oral Maxillofac Surg. 2000;38:244.CrossRef Worrall SF. TNM Classification of malignant tumours. Br J Oral Maxillofac Surg. 2000;38:244.CrossRef
17.
Zurück zum Zitat Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.PubMedPubMedCentralCrossRef Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Takamori S, Toyokawa G, Shimokawa M, Kinoshita F, Kozuma Y, Matsubara T, et al. A novel prognostic marker in patients with non-small cell lung cancer: Musculo-immuno-nutritional score calculated by controlling nutritional status and creatine kinase. J Thorac Dis. 2019;11:927–35.PubMedPubMedCentralCrossRef Takamori S, Toyokawa G, Shimokawa M, Kinoshita F, Kozuma Y, Matsubara T, et al. A novel prognostic marker in patients with non-small cell lung cancer: Musculo-immuno-nutritional score calculated by controlling nutritional status and creatine kinase. J Thorac Dis. 2019;11:927–35.PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Matsubara T, Takamori S, Haratake N, Fujishita T, Toyozawa R, Ito K, et al. Identification of the best prognostic marker among immunonutritional parameters using serum C-reactive protein and albumin in non-small cell lung cancer. Ann Surg Oncol. 2021;28:3046–54.PubMedCrossRef Matsubara T, Takamori S, Haratake N, Fujishita T, Toyozawa R, Ito K, et al. Identification of the best prognostic marker among immunonutritional parameters using serum C-reactive protein and albumin in non-small cell lung cancer. Ann Surg Oncol. 2021;28:3046–54.PubMedCrossRef
20.
Zurück zum Zitat Tomita M, Ayabe T, Maeda R, Nakamura K. The prognostic values of a novel preoperative inflammation-based score in Japanese patients with non-small cell lung cancer. World J Surg Oncol. 2019;10:176–80.CrossRef Tomita M, Ayabe T, Maeda R, Nakamura K. The prognostic values of a novel preoperative inflammation-based score in Japanese patients with non-small cell lung cancer. World J Surg Oncol. 2019;10:176–80.CrossRef
21.
Zurück zum Zitat Gallus S, Lugo A, Suatoni P, Taverna F, Bertocchi E, Boffi R, et al. Effect of tobacco smoking cessation on C-reactive protein levels in a cohort of low-dose computed tomography screening participants. Sci Rep. 2018;8:6–12.CrossRef Gallus S, Lugo A, Suatoni P, Taverna F, Bertocchi E, Boffi R, et al. Effect of tobacco smoking cessation on C-reactive protein levels in a cohort of low-dose computed tomography screening participants. Sci Rep. 2018;8:6–12.CrossRef
22.
Zurück zum Zitat Razi SS, Kodia K, Alnajar A, Block MI, Tarrazzi F, Nguyen D, et al. Lobectomy versus stereotactic body radiotherapy in healthy octogenarians with stage I lung cancer. Ann Thorac Surg. 2021;111:1659–65.PubMedCrossRef Razi SS, Kodia K, Alnajar A, Block MI, Tarrazzi F, Nguyen D, et al. Lobectomy versus stereotactic body radiotherapy in healthy octogenarians with stage I lung cancer. Ann Thorac Surg. 2021;111:1659–65.PubMedCrossRef
23.
Zurück zum Zitat Cao C, Wang D, Chung C, Tian D, Rimner A, Huang J, et al. A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non–small cell lung cancer. J Thorac Cardiovasc Surg. 2019;157:362-73.e8.PubMedCrossRef Cao C, Wang D, Chung C, Tian D, Rimner A, Huang J, et al. A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non–small cell lung cancer. J Thorac Cardiovasc Surg. 2019;157:362-73.e8.PubMedCrossRef
24.
25.
Zurück zum Zitat Shoji F, Miura N, Matsubara T, Akamine T, Kozuma Y, Haratake N, et al. Prognostic significance of immune-nutritional parameters for surgically resected elderly lung cancer patients: A multicentre retrospective study. Interact Cardiovasc Thorac Surg. 2018;26:389–94.PubMedCrossRef Shoji F, Miura N, Matsubara T, Akamine T, Kozuma Y, Haratake N, et al. Prognostic significance of immune-nutritional parameters for surgically resected elderly lung cancer patients: A multicentre retrospective study. Interact Cardiovasc Thorac Surg. 2018;26:389–94.PubMedCrossRef
26.
Zurück zum Zitat Fukumoto K, Mori S, Shintani Y, Okami J, Ito H, Ohtsuka T, et al. Impact of the preoperative body mass index on the postoperative outcomes in patients with completely resected non-small cell lung cancer: A retrospective analysis of 16,503 cases in a Japanese Lung Cancer Registry Study. Lung Cancer. 2020;149:120–9.PubMedCrossRef Fukumoto K, Mori S, Shintani Y, Okami J, Ito H, Ohtsuka T, et al. Impact of the preoperative body mass index on the postoperative outcomes in patients with completely resected non-small cell lung cancer: A retrospective analysis of 16,503 cases in a Japanese Lung Cancer Registry Study. Lung Cancer. 2020;149:120–9.PubMedCrossRef
27.
Zurück zum Zitat Tsukioka T, Nishiyama N, Izumi N, Mizuguchi S, Komatsu H, Okada S, et al. Sarcopenia is a novel poor prognostic factor in male patients with pathological Stage I non-small cell lung cancer. Jpn J Clin Oncol. 2017;47:363–8.PubMedCrossRef Tsukioka T, Nishiyama N, Izumi N, Mizuguchi S, Komatsu H, Okada S, et al. Sarcopenia is a novel poor prognostic factor in male patients with pathological Stage I non-small cell lung cancer. Jpn J Clin Oncol. 2017;47:363–8.PubMedCrossRef
28.
Zurück zum Zitat Batchelor TJP, Rasburn NJ, Abdelnour-Berchtold E, Brunelli A, Cerfolio RJ, Gonzalez M, et al. Guidelines for enhanced recovery after lung surgery: Recommendations of the Enhanced Recovery after Surgery (ERAS®) Society and the European Society of Thoracic Surgeons (ESTS). Eur J Cardiothorac Surg. 2019;55:91–115.PubMedCrossRef Batchelor TJP, Rasburn NJ, Abdelnour-Berchtold E, Brunelli A, Cerfolio RJ, Gonzalez M, et al. Guidelines for enhanced recovery after lung surgery: Recommendations of the Enhanced Recovery after Surgery (ERAS®) Society and the European Society of Thoracic Surgeons (ESTS). Eur J Cardiothorac Surg. 2019;55:91–115.PubMedCrossRef
29.
Zurück zum Zitat Wu Y-L, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in resected EGFR-mutated non–small-cell lung cancer. N Engl J Med. 2020;383:1711–23.PubMedCrossRef Wu Y-L, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in resected EGFR-mutated non–small-cell lung cancer. N Engl J Med. 2020;383:1711–23.PubMedCrossRef
30.
Zurück zum Zitat Yoh K, Takamochi K, Shukuya T, Hishida T, Tsuboi M, Sakurai H, et al. Pattern of care in adjuvant therapy for resected Stage I non-small cell lung cancer: Real-world data from Japan. Jpn J Clin Oncol. 2019;49:63–8.PubMedCrossRef Yoh K, Takamochi K, Shukuya T, Hishida T, Tsuboi M, Sakurai H, et al. Pattern of care in adjuvant therapy for resected Stage I non-small cell lung cancer: Real-world data from Japan. Jpn J Clin Oncol. 2019;49:63–8.PubMedCrossRef
Metadaten
Titel
The C-reactive protein to albumin ratio is a prognostic factor for stage I non-small cell lung cancer in elderly patients: JACS1303
verfasst von
Takuro Miyazaki
Hisashi Saji
Hiroshige Nakamura
Takeshi Nagayasu
Norihito Okumura
Masanori Tsuchida
Makoto Sonobe
Keiju Aokage
Masayuki Nakao
Tomohiro Haruki
Morihito Okada
Kenji Suzuki
Masayuki Chida
Ichiro Yoshino
Committee for Scientific Affairs, The Japanese Association for Chest Surgery
Publikationsdatum
24.02.2022
Verlag
Springer Nature Singapore
Erschienen in
Surgery Today / Ausgabe 10/2022
Print ISSN: 0941-1291
Elektronische ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-022-02485-9

Weitere Artikel der Ausgabe 10/2022

Surgery Today 10/2022 Zur Ausgabe

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Häusliche Gewalt Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.